Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2

Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2

Blog Article

Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide.Decylubiquinone (DUb), a coenzyme Q10 analog, was reported to inhibit breast cancer growth and metastasis by us.However, the influence of DUb on CRC remains unclear.Herein, we found that DUb significantly inhibited kbrovet-ca1 chewable tablets for dogs CRC growth in the patient-derived xenograft (PDX) and CT26 xenograft models.

DUb was further identified to significantly suppress CRC cell proliferation, colony formation, migration and invasion in a dose-dependent manner, while not inhibiting CRC cell apoptosis from flow cytometry assay.Sirtuin2 (SIRT2), a member of the sirtuin protein family, plays a critical role in growth and metastasis in various cancers.Moreover, DUb inhibited CRC progression by mitski nsfw upregulating SIRT2.These findings reveal that DUb has the potential to a novel drug for the treatment of CRC by inhibiting CRC cell proliferation.